CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.1205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Yu Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Foundation of 2018 Beijing Key Clinical Specialty Construction Project-Pediatrics, National Natural Science Foundation of China, Peking University People's Hospital.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Chemotherapy has been the primary treatment for patients with B-cell acute lymphoblastic leukemia (B-ALL). However, there are still patients who are not sensitive to chemotherapy, including those with refractory/relapse (R/R) disease and those experiencing minimal residual disease (MRD) re-emergence. Chimeric antigen receptor-T lymphocytes (CAR-T) therapy may provide a new treatment option for these patients.Materials and Methods Our institution conducted a single-arm prospective clinical trial (ChiCTR-OPN-17013507) using CAR-T-19 to treat R/R B-ALL and MRD re-emergent patients. One hundred and fifteen patients, aged 1-25 years (median age, 8 years), were enrolled, including 67 R/R and 48 MRD re-emergent CD19-positive B-ALL patients.
Results
All patients achieved morphologic complete remission (CR), and within 1 month after infusion, 111 out of 115 (96.5%) patients achieved MRD-negative CR. With a median follow-up time of 48.4 months, the estimated 4-year leukemia-free survival (LFS) rate and overall survival (OS) rate were 68.7%±4.5% and 70.7%±4.3%, respectively. There were no significant differences in long-term efficacy observed among patients with different disease statuses before infusion (4-year OS: MRD re-emergence vs. R/R B-ALL, 70.6%±6.6% vs. 66.5%±6.1%, p=0.755; 4-year LFS: MRD re-emergence vs. R/R B-ALL, 67.3%±7.0% vs. 63.8%±6.2%, p=0.704). R/R B-ALL patients bridging to transplantation after CAR-T treatment had a superior OS and LFS compared to those who did not. However, for MRD re-emergent patients, there was no significant difference in OS and LFS, regardless of whether they underwent hematopoietic stem cell transplantation or not.
Conclusion
CD19 CAR-T therapy effectively and safely cures both R/R B-ALL and MRD re-emergent patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.
Förderung
- Foundation of 2018 Beijing Key Clinical Specialty Construction Project-Pediatrics
- National Natural Science Foundation of China
- Peking University People's Hospital
- Peking University People’s Hospital
Zitieren
APA
Wang, Y., Xue, Y. J., Zuo, Y. X., Jia, Y. P., Lu, A. D., Zeng, H. M., & Zhang, L. P. (2024). CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1205
Vancouver
Wang Y, Xue YJ, Zuo YX, Jia YP, Lu AD, Zeng HM, et al. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.1205
BibTeX
@article{Wang2024,
author = {Wang, Yu and Xue, Yu-Juan and Zuo, Ying-Xi and Jia, Yue-Ping and Lu, Ai-Dong and Zeng, Hui-Min and Zhang, Le-Ping},
title = {CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.1205}
}
EUVIMED